Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.

Ferric carboxymaltose corrects anaemia in peritoneal dialysis patients

14 Jan 2020

Treatment with intravenous (IV) ferric carboxymaltose (FCM) safely and effectively treats iron-deficiency anaemia in patients undergoing peritoneal dialysis (PD), as shown in a recent study.

The safety analysis included 91 PD patients (mean age, 57.7 years) who initiated FCM treatment, while the efficacy analysis involved 70 patients (mean age, 50.9 years). All patients had available follow-up data of up to 12 months.

There was no hypersensitivity reaction documented, nor were there instances of FCM discontinuation or dose adjustment due to a serious adverse event (SAE). The most common non-SAEs were headache (four events), mild hypotension (three events) and hypertension (two events), among others.

In terms of efficacy, a large portion of patients achieved ferritin levels of 200–800 ng/mL (68.6 percent), transferrin saturation (TSAT) >20 percent (78.4 percent), and TSAT >20 percent and ferritin >200 ng/mL (62.8 percent) after 12 months of FCM initiation (p<0.01). Haemoglobin (Hb) levels remained at >11 g/dL with a lower dose of darbepoetin throughout the follow-up.

A subgroup analysis of patients naïve to IV iron and with absolute vs relative iron deficiency (n=51) revealed that 76.5 percent had ferritin levels >200 ng/mL, 80.4 percent had TSAT >20 percent, and Hb levels increased (1.2 g/dL) following 4 months of FCM treatment (p<0.01).

Although prospective studies are warranted, the present data indicate that “a high-dose and low-frequency strategy with FCM concurrent with routine hospital visits could be easily adapted to home PD,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.